Scientists probe gene link to MS Drug's side effects
NCT ID NCT04410965
Summary
This study aimed to understand if a specific gene mutation (ABCG2) affects how much of the multiple sclerosis drug teriflunomide stays in a patient's body and its safety. It involved 82 Chinese patients with relapsing multiple sclerosis who took the standard 14 mg dose daily for 24 weeks. Researchers compared patients with and without the gene mutation to see if it influenced drug levels or side effects like liver issues or hair thinning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number
China, China
Conditions
Explore the condition pages connected to this study.